Piper Jaffray Companies reiterated their buy rating on shares of ABIOMED, Inc. (NASDAQ:ABMD) in a research note published on Tuesday. The firm currently has a $160.00 target price on the medical equipment provider’s stock.

ABMD has been the topic of a number of other reports. Jefferies Group LLC reaffirmed a buy rating and set a $175.00 price objective on shares of ABIOMED in a report on Tuesday. BidaskClub downgraded ABIOMED from a buy rating to a hold rating in a report on Saturday, August 26th. Zacks Investment Research downgraded ABIOMED from a buy rating to a hold rating in a report on Monday, August 7th. Morgan Stanley reaffirmed an equal weight rating and set a $140.00 price objective (up from $135.00) on shares of ABIOMED in a report on Monday, July 10th. Finally, William Blair reaffirmed an outperform rating on shares of ABIOMED in a report on Thursday, June 8th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. ABIOMED has an average rating of Buy and a consensus target price of $158.29.

Shares of ABIOMED (NASDAQ ABMD) opened at 151.06 on Tuesday. The firm has a market cap of $6.63 billion, a PE ratio of 88.34 and a beta of 0.22. The firm’s 50-day moving average price is $149.26 and its 200 day moving average price is $135.36. ABIOMED has a 52 week low of $95.14 and a 52 week high of $157.41.

ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. ABIOMED had a return on equity of 13.03% and a net margin of 16.13%. The business had revenue of $132.47 million for the quarter, compared to the consensus estimate of $130.83 million. During the same period last year, the business earned $0.29 earnings per share. The firm’s revenue for the quarter was up 28.6% compared to the same quarter last year. Equities analysts anticipate that ABIOMED will post $2.24 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “ABIOMED’s (ABMD) “Buy” Rating Reiterated at Piper Jaffray Companies” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/02/abiomeds-abmd-buy-rating-reiterated-at-piper-jaffray-companies.html.

In other ABIOMED news, Director Paul Thomas sold 10,000 shares of ABIOMED stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $154.71, for a total transaction of $1,547,100.00. Following the sale, the director now directly owns 12,172 shares of the company’s stock, valued at $1,883,130.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Eric A. Md Rose sold 23,018 shares of ABIOMED stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $151.09, for a total value of $3,477,789.62. Following the sale, the director now directly owns 24,652 shares in the company, valued at $3,724,670.68. The disclosure for this sale can be found here. Insiders have sold 50,500 shares of company stock worth $7,603,342 over the last ninety days. Company insiders own 7.00% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the stock. Huntington National Bank bought a new stake in ABIOMED during the second quarter worth $100,000. Seven Eight Capital LP purchased a new position in ABIOMED during the second quarter worth about $100,000. Creative Planning boosted its position in ABIOMED by 16.4% in the first quarter. Creative Planning now owns 916 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 129 shares during the period. Virginia Retirement Systems ET AL purchased a new position in ABIOMED during the first quarter worth about $200,000. Finally, Palladium Partners LLC purchased a new position in ABIOMED during the first quarter worth about $211,000. 89.84% of the stock is currently owned by institutional investors.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Stock Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related stocks with our FREE daily email newsletter.